• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Santen Pharmaceutical Co., Ltd. - Product Pipeline Review - Q4 2010 Product Image

Santen Pharmaceutical Co., Ltd. - Product Pipeline Review - Q4 2010

  • Published: November 2010
  • Region: Global
  • 60 pages
  • GlobalData

Santen Pharmaceutical Co., Ltd. – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Santen Pharmaceutical Co., Ltd. - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Santen Pharmaceutical Co., Ltd. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Santen Pharmaceutical Co., Ltd. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, READ MORE >



List of Tables
List of Figures
Santen Pharmaceutical Co., Ltd. Snapshot
Santen Pharmaceutical Co., Ltd. Overview
Key Information
Key Facts
Santen Pharmaceutical Co., Ltd. – Research and Development Overview
Key Therapeutic Areas
Santen Pharmaceutical Co., Ltd. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Santen Pharmaceutical Co., Ltd. – Pipeline Products Glance
Santen Pharmaceutical Co., Ltd. – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Santen Pharmaceutical Co., Ltd. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Santen Pharmaceutical Co., Ltd.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Santen Pharmaceutical Co., Ltd. – Drug Profiles
CS-011
Product Description
Mechanism of Action
R&D Progress
TAFLOTAN
Product Description
Mechanism of Action
R&D Progress
DE-090
Product Description
Mechanism of Action
R&D Progress
DE-094
Product Description
Mechanism of Action
R&D Progress
DE-098
Product Description
Mechanism of Action
R&D Progress
DE-099
Product Description
Mechanism of Action
R&D Progress
DE-101
Product Description
Mechanism of Action
R&D Progress
DE-102
Product Description
Mechanism of Action
R&D Progress
DE-105
Product Description
Mechanism of Action
R&D Progress
Perceiva + Lucentis
Product Description
Mechanism of Action
R&D Progress
DE-105
Product Description
Mechanism of Action
R&D Progress
ATL313
Product Description
Mechanism of Action
R&D Progress
Santen Pharmaceutical Co., Ltd. – Pipeline Analysis
Santen Pharmaceutical Co., Ltd. – Pipeline Products by Therapeutic Class
Santen Pharmaceutical Co., Ltd. Pipeline Products By Target
Santen Pharmaceutical Co., Ltd. – Pipeline Products by Route of Administration
Santen Pharmaceutical Co., Ltd. – Pipeline Products by Molecule Type
Santen Pharmaceutical Co., Ltd. - Dormant Projects
Santen Pharmaceutical Co., Ltd. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
DE-104
Olvance
Santen Pharmaceutical Co., Ltd. – Company Statement
Santen Pharmaceutical Co., Ltd. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
May 06, 2010: Santen Launches TAFLOTAN In Korea For Treatment Of Glaucoma And Ocular Hypertension
Apr 16, 2010: Santen And Inspire Announce Approval Of DIQUAS For Treatment Of Dry Eye In Japan
Mar 02, 2010: Santen Files Manufacturing And Marketing Approval Of DE-108 In Japan
Mar 02, 2010: Santen Files Manufacturing And Marketing Approval Of DE-108 In Japan
Oct 21, 2009: MacuSight Receives Fast Track Designation From FDA For Perceiva In Treatment Of Diabetic Macular Edema
Sep 30, 2009: MacuSight Provides Clinical Development Update For Perceiva
Sep 03, 2009: Merck Launches SAFLUTAN(R) (Tafluprost) In International Markets
Sep 03, 2009: Merck Launches SAFLUTAN(R) (Tafluprost) In International Markets
Apr 15, 2009: Merck & Co., Inc. And Santen Pharmaceutical Co., Ltd. Announce Licensing Agreement For Tafluprost
Mar 03, 2009: Santen To Launch Sante FX V Plus OTC Eye Drop In Japan
Financial Deals Landscape
Santen Pharmaceutical Co., Ltd., Deals Volume Summary, 2004 to YTD 2010
Santen Pharmaceutical Co., Ltd., Deals Summary By Region, 2004 to YTD 2010
Santen Pharmaceutical Co., Ltd., Deals Summary, 2004 to YTD 2010
Santen Pharmaceutical Co., Ltd. Detailed Deal Summary
Asset Purchase
Santen Pharmaceutical Acquires Marketing Rights For RESCULA From R-Tech Ueno
Bausch & Lomb Enters Into Agreement With Santen Pharmaceutical
Santen Pharmaceutical Enters Into Co-Development Agreement With UBE Industries
CytoPathfinder Enters Into Research Agreement With Santen Pharmaceutical
Santen Pharmaceutical Enters Into Agreement With Sankyo
Santen Pharmaceutical Enters Into Co-development Agreement With Argenes
Licensing Agreements
Merck & Co Enters Into Licensing Agreement With Santen Pharmaceutical
Santen Pharmaceutical Enters Into Licensing Agreement With MacuSight
Oakwood Laboratories Enters Into Licensing Agreement With Santen Pharmaceutical
Ono Pharmaceutical Enters Into Licensing Agreement With Santen Pharmaceutical
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Note: Product cover images may vary from those shown

RELATED PRODUCTS